仙乐健康(300791) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥958,074,965.43, representing a 41.55% increase year-over-year[4] - Net profit attributable to shareholders was ¥83,962,174.96, up 26.73% compared to the same period last year[4] - Basic earnings per share increased by 25.72% to ¥0.47, while diluted earnings per share also rose by 25.72% to ¥0.47[4] - Operating income for the year-to-date reached ¥2,502,922,802.68, a 39.96% increase from the previous year[11] - Total operating revenue for Q3 2023 reached CNY 2,502,922,802.68, a significant increase from CNY 1,788,261,949.33 in the previous period[25] - The company reported a net profit of CNY 196,733,410.44 for Q3 2023, compared to CNY 202,390,033.57 in the same period last year[26] - The net profit for Q3 2023 was approximately ¥159.7 million, a decrease from ¥176.2 million in Q3 2022, representing a decline of about 9.5%[27] - The net profit attributable to shareholders of the parent company increased to ¥185.1 million from ¥176.2 million, showing a growth of approximately 5.0%[27] - Total comprehensive income for Q3 2023 reached ¥233.3 million, compared to ¥175.0 million in the same period last year, marking an increase of about 33.4%[27] - Basic earnings per share rose to ¥1.03 from ¥0.98, reflecting an increase of approximately 5.1%[28] Assets and Liabilities - Total assets as of September 30, 2023, amounted to ¥4,902,661,941.67, reflecting a 17.13% increase from the end of the previous year[5] - The company's total assets increased to CNY 4,902,661,941.67, up from CNY 4,185,817,139.24 year-over-year[22] - Non-current assets totaled CNY 3,168,983,530.78, compared to CNY 1,753,260,348.96 in the previous year[22] - Current liabilities rose to CNY 552,691,227.03, compared to CNY 469,693,040.40 in the same period last year[23] - The total liabilities of the company reached CNY 1,928,266,296.37, an increase from CNY 1,484,293,151.85 year-over-year[23] - The company's equity attributable to shareholders increased to CNY 2,860,347,399.67, compared to CNY 2,701,523,987.39 in the previous year[23] Cash Flow - Cash flow from operating activities decreased by 15.07% year-to-date, totaling ¥292,572,487.65[4] - Cash flow from operating activities generated a net amount of ¥292.6 million, down from ¥344.5 million in the previous year, indicating a decrease of about 15.1%[29] - Cash flow from investing activities decreased significantly by 1564.70% to -1,146,883,401.14 CNY, primarily due to the acquisition of Best Formulations[13] - Cash flow from investing activities resulted in a net outflow of approximately ¥1.15 billion, compared to a smaller outflow of ¥68.9 million in the same period last year[30] - As of September 30, 2023, the company's cash and cash equivalents amounted to 490,560,333.60 CNY, a significant decrease from 1,501,602,794.16 CNY at the beginning of the year[20] - Cash and cash equivalents at the end of Q3 2023 totaled ¥474.8 million, a significant decrease from ¥923.4 million at the end of Q3 2022, representing a decline of about 48.6%[30] Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,640, with the largest shareholder, Guangdong Guanghui Investment Co., Ltd., holding 43.08% of shares[15] - The top three shareholders, including Lin Peiqing and Chen Qiong, collectively hold 59.74% of the company's shares, indicating a strong concentration of ownership[15] - Lin Peiqing, as a major shareholder, directly holds 12,960,000 shares (7.18%) and indirectly holds 39,830,227 shares (22.07%), totaling 34.61% of the company's shares[16] - The company has a total of 30,530,549 restricted shares, with 2,721,600 shares released during the reporting period[18] - The company has no preferred shareholders or significant changes in restricted shares during the reporting period[17] Expenses and Costs - The company reported a significant increase in inventory, which rose by 78.31% to ¥414,714,113.87, primarily due to the consolidation of Best Formulations[10] - The company experienced a 113.85% increase in selling expenses, totaling ¥185,346,698.10, attributed to increased marketing activities and the consolidation of Best Formulations' sales expenses[11] - The company reported a 41.85% increase in operating costs, amounting to ¥1,748,274,556.78, in line with revenue growth[11] - Total operating costs amounted to CNY 2,305,834,727.33, compared to CNY 1,602,274,302.76 in the same period last year[26] - Research and development expenses for Q3 2023 were CNY 75,471,289.32, up from CNY 60,745,994.30 in the previous year[26] - The company reported a tax expense of approximately ¥37.0 million, up from ¥26.2 million in the same period last year, indicating an increase of about 41.5%[27] Strategic Activities - The company is actively pursuing market expansion and strategic acquisitions, as evidenced by the recent acquisition of Best Formulations[13] - The acquisition of Best Formulations resulted in a substantial increase in goodwill, which rose by 230.50% to ¥538,895,095.50[10] - The company has established a strong governance structure with key shareholders having familial ties, which may influence decision-making processes[16] Audit Information - The company has not undergone an audit for the Q3 2023 report[31]